Corpusense

Revvity (RVTY) earnings call transcript summary & sentiment

Last call Tue 4 Aug 2026·Next Fri 23 Oct 2026

Our read on the 4 August 2026 earnings call

Overall tone: Positive

Overall tone

Positive

Executive Summary

Revvity reported $711 million in total pro forma revenue for the quarter with 3% pro forma organic growth and adjusted EPS of $1.41, topping upper-end guidance.

Core Signals

Revenue Growth & Demand: Pro forma organic revenue grew 3% in the quarter to $711 million, driven by 11% organic growth in diagnostics despite a 3% organic decline in Life Sciences.

Bullish Signals

Full-year organic growth outlook was raised to 4–5%, adjusted operating margins to 28.7%, and full-year EPS guidance to $5.30–$5.40.

Risk Signals

Signals software organic revenue contracted 20% in the quarter, placing heavy pressure on second-half renewals to meet targets.

Q&A Signals

Repeated analyst topics: Analysts repeatedly questioned instrument backlog metrics, the timeline for reagent pull-through, and details surrounding AI-driven order sources.

Key Investor Debate

The key investor debate centers on whether the surge in AI-driven instrument orders represents an inflection point in biopharma capex spending or a localized instrument upgrade cycle that may lag in converting into high-margin reagent consumption.

Analyst Takeaway

Revvity showed solid operational execution, expanding margins while successfully capturing incremental AI-driven preclinical demand.

Those are the opening lines. The full read covers the whole earnings transcript: every bullish and bearish signal, what analysts pressed hardest on, and where management answered vaguely — each with the quote behind it. Every line sourced.

See the full Earnings Highlight

Themes across Revvity and the Health Care sector

Analyse a theme over quarters — what's brand new, what's being talked about more, and what is spreading to more companies across the sector.

Unlock themes

Ask about Revvity's earnings, or other S&P 500 earnings calls

Ask across the corpus, instead of reading one call at a time. Scope it to Revvity, its sector, or every name we cover — plain English, no operators — and answers come back structured: a summary, the drivers, and a read on each company.

"What did Revvity say about margins, and did the framing change from last quarter?"

"Did Revvity's management walk back any full-year guidance, and how did they frame it?"

"Where did Revvity avoid answering on capital allocation?"

Unlock search

Earnings call history & sentiment

Date Day Period Corpusense read
2026-08-04Tuesday2026 Q3Positive
2026-05-05Tuesday2026 Q2Positive
2026-02-02Monday2026 Q1Positive
2025-10-27Monday2025 Q4—
2025-07-28Monday2025 Q3—
2025-04-28Monday2025 Q2—
2025-01-31Friday2025 Q1—

Earnings calls across Health Care Equipment & Supplies

The companies Revvity is read alongside. Each has its own earnings call dates and sentiment.

ABTAbbott LaboratoriesALGNAlign TechnologyBAXBaxter InternationalBDXBecton DickinsonBSXBoston ScientificCOOCooper Companies (The)DXCMDexcomEWEdwards Lifesciences

Revvity is one of the S&P 500 companies we track

Sentiment analysis on any single earnings call, themes building across a sector, and search across every company and quarter — each claim linked back to the passage it came from.

Create a free account See the full calendar Plans & pricing